Nicorandil protects ATP-sensitive potassium channels against oxidation-induced dysfunction in cardiomyocytes of aging

Stéphanie Raveaud1, Jean Verdetti, Gilles Faury

  • 1Université Joseph Fourier, Grenoble, France.

Biogerontology
|November 18, 2008
PubMed

Insights

Nicorandil, a K(ATP) channel opener, protects aged heart cells by restoring normal ATP-sensitive potassium channel activity. This antioxidant effect offers potential therapeutic benefits for cardiovascular health in aging populations.

Area of Science:

  • Cardiovascular Physiology
  • Pharmacology
  • Cellular Electrophysiology

Background:

  • ATP-sensitive potassium channels (K(ATP) channels) are crucial for regulating vascular tone and cardiac function.
  • Aging and disease impair K(ATP) channel activity, necessitating treatments to improve cardiovascular health.
  • Nicorandil is a known K(ATP) channel opener with vasodilatory, antihypertensive, and cardioprotective properties.

Purpose of the Study:

  • To investigate the chronic effects of a low dose of nicorandil on cardiomyocyte K(ATP) channel activity across different age groups.
  • To assess nicorandil's protective and antioxidant actions on K(ATP) channels, particularly in aged cardiomyocytes.

Main Methods:

  • Utilized the patch-clamp technique to record cardiomyocyte K(ATP) channel activity.
  • Administered a chronic low dose of nicorandil (0.1 mg/kg/day for 2 months) to rats of varying ages (newborn, 4, 12, and 24 months).

Main Results:

  • Nicorandil demonstrated antioxidant and protective effects on cardiomyocyte K(ATP) channels.
  • These beneficial effects were most pronounced in aged animals, restoring normal channel activity.
  • The findings suggest a mechanism for nicorandil's cardioprotective actions in aging.

Conclusions:

  • Chronic low-dose nicorandil effectively protects cardiomyocyte K(ATP) channels, especially in aged hearts.
  • Nicorandil's ability to restore normal channel function supports its therapeutic potential for age-related cardiovascular decline.
  • Further research into nicorandil's applications for enhancing cardiovascular health in aging is warranted.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...